Back to News
Market Impact: 0.15
Roche To Present New Phase 3 Divarasib, Giredestrant, Tam-Peli Data At ESMO 2026
Source: Nasdaq
Healthcare & Biotech
Genentech, a member of Roche Group, said it will present new Phase III Krascendo 1 data on divarasib in previously treated advanced G12C-mutated non-small cell lung cancer. The article text is truncated before providing further details, including the other trial and any results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
ROP0.30
More News
- Ionis Pharmaceuticals EVP research Eric Swayze sells $2,307 in stock
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others
- Crushed tech stocks bounce — plus, new doctor survey keeps us positive on Lilly
- Merck KGaA to acquire Silence Therapeutics for $1.3 billion
- Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
- Silence Therapeutics jumps 59% on Merck takeover